Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. is dated December 12, 2022, covering the month of December 2022. The filing serves primarily to notify shareholders of an Extraordinary General Meeting scheduled for January 24, 2023, at the company's offices in Tel Aviv, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notice and does not contain financial statements or performance data.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document focuses on upcoming corporate actions rather than historical financial performance.
Guidance, Outlook, and Corporate Actions
The Board of Directors has called an Extraordinary General Meeting for January 24, 2023, to address two specific proposals:
- Approval of a grant of restricted share units (RSUs) to non-executive directors, with each RSU representing one American Depository Share (ADS).
- Approval of an increase in the Company's authorized share capital.
The Board recommends that shareholders vote "FOR" these proposals. The record date for shareholders entitled to vote is December 19, 2022. No specific financial guidance or management commentary on operational outlook is included in this text.
Key Facts for Investor Verification
- Meeting Date: January 24, 2023, at 3:00 p.m. Israel time.
- Record Date: December 19, 2022, for determining voting eligibility.
- Proposals: Approval of RSUs for non-executive directors and an increase in authorized share capital.
- Proxy Deadline: Proxies must be received no later than four hours prior to the meeting.
- Position Statements: Shareholders may submit written position statements by January 15, 2023.